Menlo Park-based AI imaging company Subtle Medical announced on May 27, 2026 that the U.S. Food and Drug Administration has cleared SubtleHD (PET), its next-generation AI-powered PET image enhancement software designed to lift image quality and speed up scans on existing PET/CT and PET/MR systems. The clearance pushes Subtle Medical further into a healthcare market where AI is being asked to squeeze more throughput out of expensive imaging hardware.
Up to 75% Faster PET Scans
The company says SubtleHD (PET) supports all FDA-approved radiotracers and can enable up to 75% faster PET imaging on existing scanners. The software was validated across a broad range of accelerated low-count PET acquisitions and includes adjustable denoising levels so radiologists can match its output to their reading preferences. It also leverages anatomical CT data to further sharpen PET image reconstruction and improve quantitative consistency.
Better Quantitation, Broader Tracer Support
SubtleHD (PET) is positioned as a major upgrade over the company's earlier SubtlePET product, with better image enhancement, more accurate SUVmax quantitation and broader compatibility with newer radiotracers. That matters for fast-growing applications such as theranostics, where accurate quantitative PET underpins treatment selection and response assessment. The clearance also opens the door to imaging providers running their own cyclotrons and to advanced tracer programs that earlier-generation enhancement tools struggled to support.
Patient and Provider Impact
For patients, shorter PET exams can mean meaningful comfort gains, particularly for oncology, elderly, pediatric and critically ill populations who struggle with long acquisitions. "PET imaging demand continues to grow globally, but providers remain constrained by scanner capacity, long scan times and operational inefficiencies," Subtle Medical's Ajit Shankaranarayanan said in a statement, adding that SubtleHD (PET) is intended to help imaging centers "improve throughput, drive new revenue, increase patient access, and maximize the value of existing PET infrastructure." For health systems, shorter exam times translate into more daily slots, which can be a direct revenue lever for hospital outpatient imaging departments.
Part of a Broader AI Imaging Hub
SubtleHD (PET) joins Subtle Medical's growing portfolio spanning MRI, PET and CT. The company has framed its long-term strategy as building an "AI Imaging Hub" — a unified AI infrastructure layer across modalities, scanners and health systems aimed at standardizing image quality and helping providers scale AI adoption enterprise-wide. That vision sits alongside other recent moves in AI-assisted healthcare, including Stereotaxis' $45M acquisition of Robocath and the broader push around neuro-symbolic and efficient AI for physical systems.
Why It Matters
The clearance lands as health systems hunt for AI tools that work across existing imaging infrastructure rather than requiring new scanners. With PET demand surging on the back of expanded oncology indications and theranostics workflows, software that meaningfully shrinks scan times — without compromising quantitation — addresses one of the biggest near-term operational bottlenecks in nuclear medicine.
Reporting based on coverage from Imaging Technology News, PR Newswire, and Subtle Medical.